Skip to search formSkip to main contentSkip to account menu

buparlisib

An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

NVP-BKM120

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Efficacy of buparlisib in treating breast cancer
ABSTRACT Introduction: Breast cancer is the most frequent cancer in women. Despite a decline in breast cancer mortality… 
2016
2016
BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
Glioblastoma is an aggressive, invasive tumor of the central nervous system (CNS). There is a widely acknowledged need for anti… 
2016
2016
PI3 Kinase Pathway Mutations in Human Cancers.
Review
2016
Review
2016
Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma
AbstractAberrations in the PI3K signaling pathway are frequently observed in patients with breast cancer. Because of that, PI3K… 
2015
2015
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
2015
2015
An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study
BACKGROUND: Ruxolitinib (RUX), a JAK1/JAK2 inhibitor, has demonstrated rapid and durable reductions in splenomegaly, improvements… 
2015
2015
A phase II study of the combination of BKM120 (buparlisib) and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM).
2065 Background: BKM120 is an orally bioavailable, pan-class I PI3K inhibitor that is known to cross the blood brain barrier. The… 
2015
2015
A Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NHL)
Introduction: BKM120 is a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor. Several… 
Review
2014
Review
2014
Endocrine therapy for advanced breast cancer.
The demonstrated efficacy of pharmacologic antiestrogen therapy in treating hormone receptor-positive breast cancer has changed… 
2014
2014
Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.
2019 Background: The PI3K pathway is activated in most GBMs and represents a potential therapeutic target. Buparlisib is an oral… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)